Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- GBX | -.--% | -.--% | -.--% |
08/05 | CENTRICA : UBS raises its recommendation | CF |
08/05 | UBS Upgrades Centrica to Buy from Neutral, Lifts PT | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.18 times its sales, is clearly overvalued in comparison with peers.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Multiline Utilities
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 8.83B | - | ||
-16.29% | 89.99B | C+ | ||
+71.08% | 85.77B | C | ||
+4.11% | 51.21B | C+ | ||
+0.67% | 47.61B | B+ | ||
-1.72% | 40.71B | C+ | ||
+6.75% | 36.4B | B- | ||
+18.66% | 36.14B | B+ | ||
-19.84% | 26.39B | C | ||
+2.70% | 22.54B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CNA Stock
- CNA Stock
- Ratings Centrica plc